MURA Stock Mural Oncology (MURA, $2.08) gained +30.82% in one month, becoming one of the top market winners among penny stocks
at Tickeron.com
Loading...
A.I.dvisor analyzed 787 other stocks in the Biotechnology Industry for the month ending September 9, 2025, and discovered that of them (6) exhibited an Uptrend while of them (3) exhibited a Downtrend.
Momentum Indicator for MURA turns positive, indicating new upward trend
MURA saw its Momentum Indicator move above the 0 level on December 11, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator turned positive. In of the 40 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MURA just turned positive on December 16, 2025. Looking at past instances where MURA's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 63 cases where MURA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.641) is normal, around the industry mean (27.498). P/E Ratio (0.000) is within average values for comparable stocks, (51.030). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.891). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (323.037).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology